NZX/ASX Announcement

23 September 2024

TruScreen Group Ltd Appoints Dr. Dexter Cheung as Chair of Technology Committee

TruScreen Group Ltd ("TruScreen" or "the Company") is pleased to announce the appointment of Dr. Dexter Cheung as Chair of the Company's Technology Committee, effective immediately.

Dr. Cheung was appointed to the Board of TruScreen in March 2021 and is also a member of the Company's Finance and Audit Committee. With over 20 years of experience as a medical device engineer and specialist in product research and development, Dr. Cheung brings significant expertise to assist the board in further developing the Company's technology pathways.

Dr. Cheung is currently the Research and Development Manager for the respiratory humidification division of Fisher & Paykel Healthcare, a dual ASX/NZX-listed company. His extensive knowledge in manufacturing processes, product innovation, and medical device engineering, particularly in the field of opto-electronics, is highly relevant to TruScreen's cervical cancer screening technology, which uses opto-electronic signatures for screening results. Dr. Cheung holds a PhD, Bachelor of Technology (Hons), and Master of Engineering.

The Board congratulates Dr. Cheung on his appointment and looks forward to his continued contribution to the Company.

This announcement has been approved by the Board.

ENDS

For more information, visit www.truscreen.com or contact:

Tony Ho	Guy Robertson
Chairman	Chief Financial Officer
tonyho@truscreen.com	guyrobertson@truscreen.com

truscreen
a world without cervical cancer

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors

In financial year 2024 alone, over 200,000* examinations have been performed with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"©.

To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*